Albany, NY -- (SBWIRE) -- 10/12/2018 -- DelveInsight has announced the addition of the "Cutaneous T-cell Lymphoma (CTCL) Market Insights, Epidemiology and Market Forecast-2027" drug pipelines to their offering.

The report provides an overview of the disease and market size of CTCL for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the overview, treatment practice and Cutaneous T-cell Lymphoma (CTCL) forecasted epidemiology from 2018 to 2027 segmented by seven major markets.

Cutaneous T-Cell Lymphoma (CTCL) is a group of lymphoproliferative disorders characterized by localization of neoplastic T lymphocytes to the skin. Collectively, CTCL is classified as a type of non-Hodgkin lymphoma (NHL). Cutaneous T-cell lymphomas (CTCL) are the most common types of skin lymphoma. More than 3 out of every 4 skin lymphomas diagnosed are CTCLs. They often appear as eczema-like skin rashes and can affect widespread parts of the body. There are different subtypes of CTCL. Most are slow growing but some can be fast growing. The most common types of CTCL are Mycosis Fungoides and Sezary Syndrome.

As per DelveInsight estimates, men account for over 53% of total cases of CTCL, as compared to women. The total incident population of CTCL in the 7 major markets was ~ 8400 cases in 2016. DelveInsight estimates higher incident cases of CTCL in the United States with ~3,200 incident cases in 2016, followed by EU5 and Japan and also, there are ~1,700 cases of Mycosis fungoides in 2016 in the US. The incidence rate of Mycosis fungoides has been increasing significantly since the 1970s.

The market study carried out for the period of 2016-2027 shows that the Market Size of Cutaneous T-cell Lymphoma was about USD 698.47 Billion in 2016 in the 7MM, growing at an increasing CAGR during the forecasted period (2018-2027). The treatment of CTCL depends on the disease stage. Early stage therapies are topical, including corticosteroids, retinoids, imiquimod (Aldara), ultraviolet A irradiation (PUVA), and total skin electron beam therapy. Systemic therapies are introduced in the advanced stages where the disease is widespread and/or resistant to topical treatment. These include interferon alpha injections, stem cell transplant, alemtuzumab (MabCampath) and other chemotherapy regimens. The FDA approved drugs include Istodax (romidepsin), Valchlor (mechlorethamine), Uvadex (methoxsalen), Targretin (bexarotene) and Zolinza (vorinostat). The United States had the highest market share of Cutaneous T-cell Lymphoma (CTCL) in 2016, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. The market size for the Early Stage First Line & Second Line Therapies of CTCL in the United States was found to be approx. USD 28.22 Million and USD 265.3 Million respectively in 2016.

Geography Covered

1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

Cutaneous T-cell Lymphoma Drug Companies
1. Medivir AB
2. 4SC AG
3. Soligenix
And many others
Drugs covered

1. SGX301
2. Remetinostat
And many others

Report Scope

The report covers a descriptive overview of the Cutaneous T-cell Lymphoma (CTCL), explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the Cutaneous T-cell Lymphoma (CTCL) and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for Cutaneous T-cell Lymphoma (CTCL) are provided, along with an assessment of the impact of new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted Cutaneous T-cell Lymphoma (CTCL) market is included in the report, covering drug outreach in 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Cutaneous T-cell Lymphoma (CTCL) market.